Becker's Healthcare November 14, 2024
Elizabeth Gregerson

A six-month shortage of cisplatin, a drug used in the treatment of head and neck cancer, resulted in a 16% total cost increase for practices in the U.S. Oncology Network, according to a study presented Sept. 27-28, at the American Society of Clinical Oncology’s 2024 Quality Care Symposium in San Francisco.

Researchers from 26 practices in The Woodlands, Texas-based U.S. Oncology Network analyzed drug administration data for the six-month periods before, during and after the cisplatin shortage, according to a Nov. 10 news release from The ASCO Post.

The cisplatin shortage began in February 2023. Though the FDA declared an official end to the shortage June 28, 2024, the study defined the shortage period from February 2023 to August...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Survey / Study, Trends
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy

Share This Article